Overview
No overview information available.
Indication
⑴治疗氰化物中毒，与高铁血红蛋白形成剂联合应用； ⑵治疗降压药硝普钠过量中毒； ⑶治疗可溶性钡盐（如硝酸钡）中毒； ⑷治疗砷、汞、铋、铅等金属中毒，但首选二巯基类药物及依地酸类药物； ⑸作为非特异性抗炎药，用于皮炎、湿疹、荨麻疹、药物性皮炎、副银屑病的治疗【1.《糖皮质激素类药物临床应用指导原则》；2.《中西医结合系统药物治疗湿疹皮炎类皮肤病专家共识》2015；3.《临床诊疗指南皮肤病与性病分册》】。
Associated Conditions
No associated conditions information available.
Research Report
A Comprehensive Monograph on Sodium Thiosulfate: From Chemical Commodity to Targeted Therapeutic Agent
I. Introduction and Executive Summary
Overview
Sodium Thiosulfate, with the chemical formula Na2S2O3, is an inorganic salt that has traversed a remarkable path from a widely used industrial and chemical commodity to a critical, life-saving medication and a targeted therapeutic agent in modern medicine.[1] Historically known to photographers as "hypo" for its role in fixing photographic film, its applications have expanded into diverse fields, including water treatment as a dechlorinating agent and analytical chemistry as a titrant.[1] However, its most profound impact lies in its medical applications. For nearly a century, it has been a cornerstone in the treatment of acute cyanide poisoning, a role that cemented its place in emergency medicine.[3] More recently, rigorous clinical investigation has led to its approval by major global regulatory bodies for a highly specific and novel indication: the prevention of permanent, debilitating hearing loss (ototoxicity) in pediatric cancer patients undergoing cisplatin chemotherapy.[5] This evolution from a bulk chemical to a precision supportive care drug highlights a sophisticated understanding of its unique chemical reactivity and its translation into distinct, context-dependent pharmacological effects.
Executive Summary
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/03/01 | Not Applicable | Not yet recruiting | Alp Sener | ||
2023/03/06 | Early Phase 1 | Suspended | |||
2022/05/19 | Phase 3 | Recruiting | |||
2021/08/24 | Phase 3 | Recruiting | |||
2021/04/15 | Phase 1 | Recruiting | |||
2020/09/09 | Phase 2 | Completed | Hyunseok Kang, MD | ||
2020/07/20 | Phase 3 | Recruiting | Shanghai Children's Medical Center | ||
2020/02/10 | Phase 1 | Completed | Decibel Therapeutics | ||
2020/02/05 | Phase 2 | UNKNOWN | Soraia Azevedo | ||
2019/12/30 | Early Phase 1 | Terminated |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc. | 73077-010 | INTRAVENOUS | 12.5 g in 100 mL | 9/30/2022 | |
| Hope Pharmaceuticals | 60267-705 | INTRAVENOUS | 250 mg in 1 mL | 11/16/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 5/26/2023 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| SODIUM THIOSULFATE INJ 25% USP | david bull laboratories (pty) ltd. | 01908820 | Liquid - Intravenous | 250 MG / ML | 12/31/1991 |
| SEACALPHYX | seaford pharmaceuticals inc | 02386666 | Solution - Intravenous | 250 MG / ML | 1/8/2013 |
| ADASEPT ACNE GEL | odan laboratories ltd | 00326577 | Lotion - Topical | 8 % | 12/31/1974 |
| SODIUM THIOSULFATE INJECTION USP | 02137186 | Solution - Intravenous | 250 MG / ML | 7/13/1998 | |
| SODIUM THIOSULFATE INJECTION USP | 02428393 | Solution - Intravenous | 250 MG / ML | 11/23/2015 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.